- Unlike other sectors that were adversely impacted by the pandemic, healthcare companies fared well in 2020.
- Ryman Healthcare Limited witnessed witnessed a 12.8% rise in the reported (IFRS) profit taking it to $212.4m in its interim results.
- Fisher & Paykel Healthcare Corporation noted 73% increase in the operating revenue for the period of 9 months ending December last year.
In the past year, several industries witnessed fluctuations, businesses came to a standstill, trade was disrupted due to COVID-19 and the several implications it brought about with it.
However, healthcare industry escaped unscathed from adverse repercussions of the coronavirus and witnessed growing demand in its products and services. As a consequence, several healthcare companies experienced increased profits during the period.
Source: © Scanrail | Megapixl.com
Let’s have a look at some leading NZX listed healthcare companies and see how they fared amidst the crisis.
Ryman Healthcare Limited (NZX:RYM)
One of the leading NZX listed healthcare companies, Ryman Healthcare performed fairly well despite the COVID-19 related restrictions. While there was a 14.2% drop to $88.4m in the unaudited underlying profits in half yearly report ended 30 September 2020. Further, the Company witnessed a 12.8% rise in the reported (IFRS) profit taking it to $212.4m. The Company also announced an interim dividend for its shareholders (standing at 8.8 cents per share) for the six-month period.
On 5 February, Ryman Healthcare last traded at $15.85, up by 0.44%.
Fisher & Paykel Healthcare Corporation (NZX:FPH)
Leading medical equipment producer, Fisher & Paykel witnessed a very strong trading despite COVID-19 in the year 2020.
It was revealed on 22 January that the Company saw a 73% increase in the operating revenue for the period of 9 months that ended on December 31, 2020. Also, during the same period, on the Hospital product group front, there was a 113% growth in operating revenue. In the same period, there was 54% increase in hospital consumables whereas the hospital hardware saw an increase of as much as 446% (in constant currency).
On 5 February, Fisher & Paykel Healthcare last traded at $33.50, down by 1.30%.
Ebos Group Limited (NZX:EBO)
Healthcare and marketing distribution company, Ebos Group fared well in the year 2020, despite the many COVID-19 related challenges.
The same reflects in its annual report released in August for the period ended June 2020. There was a 26.5% revenue increase standing at $8.8billion. There was an 18% increase in the NPAT, to $162.5 million and 13.4% increase noted for underlying EBITDA standing at $296.6million.
On 5 February, Ebos Group last traded at $29.40, up by 0.62%.